Evogene Ltd Dossier
Qualitative Analysis
Business overview
Evogene Ltd. (NASDAQ/TASE: EVGN) is an Israel-based computational biology and chemistry pioneer leveraging big data and artificial intelligence to revolutionize the discovery and development of life-science-based products. The company's core technological foundation is built upon three proprietary tech-engines: MicroBoost AI (microbes), ChemPass AI (small molecules), and GeneRator AI (genetic elements). Following a decisive strategic shift initiated in 2025, Evogene has focused its core operations on computational chemistry and generative AI design of small molecules for the pharmaceutical and agricultural industries, primarily powered by its ChemPass AI platform. The company operates through a hybrid business model, utilizing strategic partnerships, collaborations, and specialized subsidiaries (such as Biomica, AgPlenus, and Casterra) to bring products to market.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Sharpening the company's strategic focus to concentrate resources on a single proprietary computational engine, ChemPass AI, for small-molecule discovery and optimization, targeting two high-impact markets: pharma and agriculture.
Expected impact: Significant reduction in annual operating expenses (down to ~$13.8 million in 2025 from ~$22 million in 2024) and improved capital efficiency.
An expanded phase of collaboration with Google Cloud to develop and integrate advanced AI Agents into the ChemPass AI platform using Google Cloud's Vertex AI platform.
Expected impact: Automate and scale key discovery processes, enable large-scale parallel molecular exploration, shorten design-make-test-analyze cycles, and improve the accuracy and success rate of designing small-molecule based products.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
High strategic importance as it integrates advanced AI agents into ChemPass AI to automate dataset generation from complex scientific workflows, shifting the platform from generative design to autonomous discovery.
Terms: Terms not publicly disclosed.
Aims to develop a first-in-class therapy for demyelinating disorders like Multiple Sclerosis (MS) by combining Evogene's ChemPass AI with Unravel's BioNAV platform to design brain-penetrant inhibitors.
Terms: Terms not publicly disclosed.
Focuses on discovering and optimizing novel small molecules to overcome chemotherapy resistance in non-small cell lung cancer (NSCLC) based on cellular detoxification pathways.
Terms: Terms not publicly disclosed.
Backed by a pan-European EUREKA grant to develop targeted small-molecule therapies for hyper-inflammatory diseases driven by dysregulated neutrophil activity, such as inflammatory bowel disease (IBD).
Terms: Supported by a pan-European EUREKA grant; specific financial splits not disclosed.
AgPlenus (Evogene's subsidiary) continues to advance novel herbicide programs through this ongoing strategic collaboration.
Terms: Terms not publicly disclosed.